Survey: Health systems push toward risk-based payment models, payer-provider partnerships
Check out the key takeaways from a survey conducted in Summer 2021 with healthcare executives, which focused on risk-based models, data issues, leaders’ concerns on hitting budgets and more.
Cost Effectiveness of Health Report, February 2022
The January 2022 edition of HFMA’s Cost Effectiveness of Health Report, sponsored by Kaufman Hall, explores key tactics successful independent community hospitals use to help them sustain their mission to the communities they serve. Also included is a preview of the first of a series of columns by hfm columnist David Johnson addressing the need for nonprofit health systems to address 5 structural defects that keep them from delivering truly high-quality care to patients.
Healthcare M&A update: A quiet 2021 could give way to strategic shifts in 2022
The year 2021 was one of the least busy on record for healthcare mergers and acquisitions, but volume should pick up in 2022.
U.S. healthcare system is poised to begin a new phase in partnerships
Healthcare provider organizations should prepare for an emerging new phase in the evolution of healthcare partnerships, characterized by an increasingly diverse array of choices among care sites and settings for consumers, health plans and employers. In responding to the opportunities presented in this new partnership phase, providers should adopt a strategy that applies important lessons learned during the pandemic.
Healthcare labor update: Employment data and research findings underscore ongoing challenges
As highlighted in new employment data and new studies, the healthcare labor market continues to constrain hospitals.
Accelerated drug approvals present a mounting challenge to oncologists and raises concerns about cost effectiveness for health system finance leaders
In the past year, Americans have witnessed two extremes of the FDA’s accelerated approval process, exposing both profound strengths and worrisome weaknesses. Finance leaders should keep informed about new drug treatment options, their associated costs and efficacy and whether lower-cost alternatives that have the same efficacy are available so they can engage in meaningful conversations with clinicians about which options truly promote cost effectiveness of health.
Payvider Survey Summary Report
HFMA, with sponsorship from Guidehouse, surveyed over 100 health system CFOs and finance and managed care executives to understand payvider model trends. The survey indicates that provider organizations are gravitating towards risk-based payment models. Nearly 60% of health systems responding to the survey plan to advance into risk-based Medicare Advantage models this year. Survey respondents…
Healthcare 2030: The Chartis Group and Bank of America discuss embracing disruptors and rethinking care delivery
Melissa McCain, director and leader of the consumer access digital transformation practice of The Chartis Group, and Charles Alston, market executive leader of Bank of America’s healthcare team in the southeastern U.S., discuss HFMA’s Healthcare 2030 series and share insights about what hospitals and health systems should be considering as they plan for the next decade.
Healthcare 2030: The Chartis Group and Bank of America discuss embracing disruptors and rethinking care delivery
Listen to the podcast. On this episode of HFMA’s Voices in Healthcare Finance podcast, Melissa McCain, director and leader of the consumer access digital transformation practice of The Chartis Group and Charles Alston, market executive leader of Bank of America’s healthcare team in the southeastern U.S., discussed HFMA’s Healthcare 2030 series and what hospitals and…
Hospital margins increased in November, but labor expenses remained a drag on finances
A skewed labor market continued to affect hospital finances in November even as operating margins improved from October.